

# Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement

written by Raj Shah | March 4, 2024

March 4, 2024 ([Source](#)) – **Voyageur Pharmaceuticals Ltd.** (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”) and **Applied Pharmaceutical Innovation** (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement (**MSA**). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative step forward for Canada’s thriving life sciences sector.

Under this strategic agreement, API will play a crucial role in accelerating Voyageur’s imaging contrast medium product development, manufacturing, and commercialization. Leveraging API’s scientific and pharmaceutical expertise, the collaboration aims to facilitate regulatory approvals and expedite the market entry of Voyageur’s contrast imaging products.

This partnership will strategically target FDA, Health Canada and other regulatory agencies, by licensing across several key development areas:

- **Accelerating the development and registration of the innovative V@C60 MRI drug** (Vanadium Fullerene Molecule for magnetic resonance imaging <https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium->

### [fullerene-molecule/](#)

- **Developing novel fullerene imaging products for targeted drug delivery within the body, with a focus on applications in Oncology.**
- **Introducing an advanced suite of new barium contrast media products, with the goal to displace current products in the market.**
- **Expanding Voyageur's Iodine contrast media product pipeline, including potential development of fullerene iodine products**
- **Developing a carbon 60 based nutraceutical health supplement**

"We are thrilled to embark on this groundbreaking collaboration with Voyageur, advancing healthcare through the commercialization of mineral-based active pharmaceutical ingredients for the medical imaging market," stated Andrew MacIsaac, CEO at API. "This partnership underscores our commitment to driving innovation and elevating the life sciences landscape in Canada and globally."

Brent Willis, CEO of Voyageur, expressed excitement about the collaboration, stating, "Our vision is to become the world's first company capable of creating new carbon-based drugs from captured CO<sub>2</sub>, ensuring carbon-neutral pharmaceuticals. This strategic alliance with API will accelerate Voyageur's development programs, with a primary focus on creating a groundbreaking carbon-based MRI drug and advancing our iodine contrast media product pipeline."

By amalgamating API's regulatory expertise with Voyageur's research and development capabilities, this partnership is poised to showcase global leadership in pharmaceutical development. The collaboration exemplifies how the intersection of Alberta's strengths in natural resources, scientific

innovation, and environmental stewardship can result in enhanced healthcare solutions worldwide. Together, API and Voyageur aim to streamline the integration of Voyageur's contrast media products, reducing supply chain risks and aiding healthcare practitioners in diagnosing diseases, disorders, and abnormalities globally.

### **About Voyageur Pharmaceuticals Ltd.:**

Voyageur (TSX Venture Exchange: VM) is a Canadian public company at the forefront of barium, iodine, and carbon Active Pharmaceutical Ingredients (API) and high-performance, cost-effective imaging contrast agents. Focused on vertically integrating the barium, iodine, and carbon contrast imaging market, Voyageur aims to become a key player by producing its own minerals.

Committed to sustainability, Voyageur envisions a future of carbon neutrality. Utilising Rain Cage Carbon Inc patented Eden System, Voyageur plans to capture carbon producing an added revenue stream to help finance operations and create the carbon used for new drug development. The Corporation holds a 100% interest in the Frances Creek property, a NI-43-101 barium sulfate (barite) project with an assigned \$344M NPV based on a 2021 preliminary economic assessment. Voyageur is building vertical integrated product lines that are all 100% carbon neutral.

### **About API:**

API stands as one of Canada's largest life sciences commercialization organizations, dedicated to enhancing the quality-of-life sciences. As an industry-funded not-for-profit, API provides end-to-end support to life sciences researchers, businesses, and innovators on their journey from idea to commercialization. With scientific leadership from Nobel

Laureate Sir Michael Houghton, API provides access to facilities and experts that help pharmaceutical projects reach the market. With a commitment to sharing expertise, resources, and infrastructure, API aims to build an unparalleled life sciences sector driving prosperity for all.

For media inquiries, please contact:

**Voyageur Pharmaceuticals Ltd.**

|  |   |
|--|---|
| <b>Brent Willis, CEO,</b>                              | <b>Albert Deslauriers, CFO,</b>   |
| <a href="mailto:Brent@vpharma.ca">Brent@vpharma.ca</a> | <a href="mailto:Albert@vpharma.ca">Albert@vpharma.ca</a>                              |
| <a href="mailto:info@vpharma.ca">info@vpharma.ca</a>   | <a href="https://voyageurpharmaceuticals.ca/">https://voyageurpharmaceuticals.ca/</a> |

**API (Applied Pharmaceutical Innovation)**

Tessa Vriend, Director, Engagement & Brand

[tessa.vriend@appliedpharma.ca](mailto:tessa.vriend@appliedpharma.ca)

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

**Cautionary Statement Regarding “Forward-Looking” Information.**

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the perceived benefits to Voyageur from entering into the MSA; Voyageur’s expectations and timing with respect to developing pharmaceutical drugs including the Va@C60 MRI drug, fullerene imaging drugs, new barium contrast drugs, iodine contrast and fullerene iodine drugs, and nutraceutical health supplements; Voyageur’s perceived costs and other benefits from its collaboration with API; Voyageur’s anticipated plans and benefits from its relationship with API; Voyageur’s

expectation that it will be able to secure the financing necessary to pursue its objectives; and other statements herein, which expressly or impliedly speak to Voyageur's expectations for its business and operations. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties, including, without limitation, global market factors and supply chain issues, risks relating to the regulation and approval of Voyageur's products, and general risks relating to Voyageur's business. There can be no assurance that such information will prove to be accurate and actual.